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OBJECTIVES We examined whether patients with atrial fibrillation (AF) have alterations in atrial inositol
1,4,5 trisphosphate receptors (IP3 receptors).
BACKGROUND Abnormal intracellular Ca21 homeostasis occurs in chronic AF. The intracellular Ca21
concentration is regulated by ryanodine and IP3 receptors. We recently reported alterations
in ryanodine receptors in atrial tissue from patients in chronic AF.
METHODS We analyzed IP3 receptor expression in the right atrial myocardium from 13 patients with
mitral valvular disease (MVD) with AF (MVD/AF), five patients with MVD who had
normal sinus rhythm (MVD/NSR) and eight control patients with NSR (tissue obtained
during coronary artery bypass surgery). Hemodynamic and echocardiographic data were
obtained preoperatively, and an immunohistochemical study was performed on atrial tissue.
RESULTS The relative expression level of IP3 receptor protein was significantly greater in MVD/AF
(0.75 6 0.26) than it was in MVD/NSR (0.42 6 0.13, p , 0.01), and both were significantly
above control (0.14 6 0.08). The relative expression level of IP3 receptor messenger RNA
was significantly greater in the MVD/AF group (0.028 6 0.008) than it was in the control
group (0.015 6 0.004, p , 0.01), but patients with MVD/AF did not differ from patients
with MVD/NSR (0.020 6 0.006). The relative expression levels of IP3 receptor protein and
messenger RNA were higher in patients with left atrial dimension $40 mm, pulmonary
capillary wedge pressure $10 mm Hg and right atrial pressure $5 mm Hg. Inositol 1,4,5
trisphosphate receptors were over-expressed in the cytosol and at the nuclear envelope of atrial
myocytes in MVD.
CONCLUSIONS Since chronic mechanical overload of the atrial myocardium increased IP3 receptor expres-
sion, especially in patients with chronic AF, up-regulation of IP3 receptors may be important
in modulating intracellular Ca21 homeostasis and initiating or perpetuating AF. (J Am Coll
Cardiol 2001;37:1111–9) © 2001 by the American College of Cardiology
Atrial fibrillation (AF) is the most frequently encountered
arrhythmia in the clinical setting. The main electrophysio-
logical mechanism underlying AF appears to be a progres-
sive decrease in atrial refractoriness, a phenomenon that has
been termed “electrical remodeling” (1). Although this
phenomenon is thought to be of importance in the self-
perpetuation of AF and although cytosolic Ca21 abnormal-
ities are an important mediator of sustained AF, the cellular
and molecular mechanisms initiating or maintaining AF
remain unclear. Recently, we reported that in the atrial tissue of
patients with chronic AF, there are alterations in ryanodine
receptors (sarcoplasmic reticulum [SR] Ca21 regulatory pro-
teins), which play an important role in regulating the intracel-
lular Ca21 concentration in cardiac muscle (2).
Two forms of intracellular Ca21 release channels serve to
regulate the intracellular Ca21 concentration: the ryanodine
receptor (RyR) and the inositol 1,4,5 trisphosphate (IP3)
receptor. Recently, an IP3 receptor was detected in both
intracellular and plasma membrane fractions of canine
pancreatic homogenates (3) and also in cardiac myocytes
(4), in which it was restricted to the region of the interca-
lated discs (5). The demonstration that both forms of Ca21
release channels are expressed in cardiac myocytes raises the
possibility that a complex feedback mechanism may exist
involving interactions between IP3 receptor and RyR Ca21
pools. Moreover, Kijima et al. (5) suggested that a possible
role of the cardiac IP3 receptor may be to mediate Ca21
entry or to modulate intercellular communication via junc-
tions.
The purpose of this study was to determine whether
patients with chronic AF have alterations in the IP3
receptor in their atrial tissue. We studied the expression
levels of IP3 receptor protein and messenger RNA (mRNA)
in the right atrium after its removal during cardiac surgery
from patients with chronic AF and from others with a
normal sinus rhythm (NSR).
METHODS
Selection of patients. We examined right atrial tissue
(atrial appendage) from: 1) 13 patients with mitral valvular
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disease (MVD) in whom AF had been sustained for more
than two years, and 2) 5 patients with MVD who had NSR;
tissue was obtained during cardiac surgery for MVD in all
18 patients. Control material (right atrial tissue from eight
patients without MVD who had NSR) was obtained during
coronary artery bypass surgery. All patients were evaluated
by the Second Department of Internal Medicine, Yamagu-
chi University School of Medicine, and they underwent
surgery at the Yamaguchi University Hospital. Informed
consent was obtained from each patient. The protocols were
in accord with guidelines laid down by the Institutional
Review Board, Yamaguchi University Hospital. Demo-
graphic data (age, gender, diagnosis and hemodynamic data)
are shown in Table 1. In addition to their usual medication,
all patients received preoperative sedation and perioperative
anesthesia. Hemodynamic and echocardiographic data were
obtained by reviewing data from preoperative cardiac cath-
eterizations and echocardiograms.
Myocardial tissue samples. Right atrial appendages were
frozen immediately and stored at 280°C until needed. They
were used to prepare a membrane fraction for a Western
blotting assay and to produce RNA for reverse transcription
polymerase chain reaction (RT-PCR) amplification.
Abbreviations and Acronyms
AF 5 atrial fibrillation
cDNA 5 complementary DNA
GAPDH 5 glyceraldehyde-3-phosphate
dehydrogenase
IP3 receptor 5 inositol 1,4,5 trisphosphate receptor
LAD 5 left atrial diameter
mRNA 5 messenger ribonucleic acid
MVD 5 mitral valvular disease
NSR 5 normal sinus rhythm
PCR 5 polymerase chain reaction
PCWP 5 pulmonary capillary wedge pressure
RAP 5 right atrial pressure
RT-PCR 5 reverse transcription-polymerase chain
reaction
RyR 5 ryanodine receptor
SR 5 sarcoplasmic reticulum
Table 1. Clinical Characteristics of Patients
Pt.
(No.) Diagnosis
Age/
Gender
EF
(%)
RAP
(mm Hg)
PCWP
(mm Hg)
LAD
(mm)
AF
Duration Presurgical Medication
MVD 1 AF
1 MVD 69/F 72 9 18 90 .3 yr Digoxin, enalapril, NTG, furosemide
2 MVD 47/M 54 6 23 56 .5 yr Digoxin, furosemide
3 MVD 63/F 72 9 12 52 .5 yr Enalapril, ISDN, furosemide, spironolactone
4 MVD 55/F 66 4 10 66 .5 yr Digoxin
5 MVD 68/M 56 1 12 88 .5 yr Benazepril, furosemide
6 MVD 73/F 62 9 14 62 .5 yr Digoxin, furosemide, spironolactone
7 MVD 72/F 64 8 26 83 .5 yr Digoxin, furosemide
8 MVD 52/M 46 2 8 62 3 yr Digoxin, enalapril, furosemide
9 MVD 47/F 58 5 15 64 2 yr Digoxin, enalapril, furosemide
10 MVD 63/F 55 9 12 52 .5 yr Digoxin, enalapril, furosemide,
spironolactone
11 MVD 57/F 56 2 15 50 .5 yr Digoxin, enalapril, spironolactone
12 MVD 51/M 67 5 12 48 .4 yr Digoxin, enalapril, furosemide,
spironolactone
13 MVD 60/F 64 6 18 54 .2 yr Digoxin, ISDN, furosemide, spironolactone
Mean 6 SD 61 6 8 6 6 3 15 6 5† 64 6 15†‡
MVD 1 NSR
1 MVD 56/F 72 5 16 46 Digoxin, enalapril, furosemide
2 MVD 64/F 67 1 24 48 Digoxin, NTG, furosemide
3 MVD 70/F 64 1 8 47 Furosemide
4 MVD 76/F 78 10 8 52 Digoxin, spironolactone
5 MVD 64/F 76 2 9 51 Alacepril, furosemide, spironolactone
Mean 6 SD 71 6 6 4 6 4 13 6 7* 49 6 3*
Control
1 IHD 66/M 60 2 7 35 Bisoprolol, ISMN, nicorandil
2 IHD 77/F 60 4 8 36 ISDN, nicorandil, nifedipine
3 IHD 72/M 70 1 2 38 Nipradilol, ISDN, diltiazem
4 IHD 57/M 72 4 7 28 Bisoprolol, ISDN, nicorandil, diltiazem
5 IHD 61/M 50 7 8 39 ISDN, diltiazem, enalapril
6 IHD 57/M 65 5 8 33 Metoprolol, ISDN, amlodipine
7 IHD 66/M 67 3 5 37 Betaxolol, ISDN, nicorandil
8 IHD 70/M 74 3 5 35 Bisoprolol, nicorandil, diltiazem, enalapril
Mean 6 SD 64 6 9 4 6 2 6 6 2 35 6 4
*p , 0.05 compared with control; †p , 0.01 compared with control; ‡p , 0.05 compared with MVD 1 NSR.
AF 5 atrial fibrillation; EF 5 left ventricular ejection fraction; IHD 5 ischemic heart disease; ISDN 5 isosorbide dinitrate; ISMN 5 isosorbide mononitrate; LAD 5 left
atrial diameter; MVD 5 mitral valvular disease; NSR 5 normal sinus rhythm; NTG 5 nitroglycerin; PCWP 5 pulmonary capillary wedge pressure; RAP 5 right atrial pressure.
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Atrial membrane preparation. A membrane preparation
was obtained by differential centrifugation as described by
Volpe et al. (6) with some modifications. Atrial tissue
(approximately 100 mg) was homogenized using a Polytron
(Kinematica, Lucerne, Switzerland) in 30 mM Tris-maleate
containing 0.3 M sucrose, 5 mg/l leupeptin and 0.1 mM
phenylmethanesulfonyl fluoride, pH 7.0 (solution A). The
homogenate was centrifuged at 5,500 3 g for 10 min, and
the supernatant was centrifuged at 12,000 3 g for 20 min.
The supernatant was incubated for 60 min in a buffer of the
following composition: 30 mM Tris-maleate, 0.3 M su-
crose, 0.6 M KCl, 5 mg/l leupeptin, 0.1 mM PMSF, pH
7.0, and centrifuged at 143,000 3 g for 30 min. The pellet
was resuspended in solution A. This fraction was rapidly
frozen in liquid nitrogen and stored at 280°C. An aliquot
was retained for protein assay using the method of Lowry et
al. (7) with bovine serum albumin standards.
Immunologic quantification of IP3 receptor protein.
Immunoblot analysis was performed as previously described
(5) with some modifications. Atrial membrane protein
(40 mg protein/lane) was electrophoresed on 4% SDS-
polyacrylamide gels using a Laemmli buffer system (8). The
proteins in the gel were transferred to a protran nitrocellu-
lose membrane (Schleicher & Schuell, Dassel, Germany).
The membranes were then treated with 5% nonfat dry milk
in phosphate-buffer, incubated with a polyclonal anti-IP3
receptor type-1 antibody (Affinity Bioreagents, Inc.,
Golden, CO) (1:1000 dilution) solution and incubated
further with peroxidase-conjugated secondary antibody (1:
1000 dilution).
The amount of protein recognized by the antibodies was
quantified by means of an ECL™ immunoblotting detec-
tion system (Amersham Pharmacia Biotech, Buckingham-
shire, England), with the membrane being exposed to X-ray
film. Quantitative densitometry of immunoblots was per-
formed using a microcomputer-imaging device (AE-
6900M, Atto, Tokyo, Japan). The relative activity associ-
ated with cardiac IP3 receptor protein in each sample was
calculated by dividing the activity associated with the IP3
receptor protein products by the activity associated with the
control (canine cerebellar IP3 receptor protein [5 mg]).
RNA preparation. Total cellular RNA was isolated from
each frozen tissue sample (approximately 50 mg) by the
method of acid guanidinium thiocyanate/phenol/
chloroform extraction (9), then stored at 280°C.
RT-PCR. Complementary DNA (cDNA) was prepared
using a Takara RNA PCR Kit (Takara, Tokyo, Japan), as
previously described (2) in a buffer containing 10 mM
Tris-HCl, pH 8.3, 50 mM KCl, 5 mM MgCl2 and 1 mM
each of dCTP, dGTP, dTTP and dATP, with 20 U of
recombinant ribonuclease inhibitor, 2.5 M random 9 mers,
1.3 mg of total RNA, 5 U of avian myeloblastosis virus
reverse transcriptase, all in a volume of 20 ml. This reaction
mixture was incubated for 10 min at 30°C followed by
30 min at 42°C to initiate the synthesis of the cDNAs.
Reverse transcriptase was inactivated at 99°C for 5 min, and
this mixture was then used for the amplification of specific
cDNAs by polymerase chain reaction (PCR). The PCR was
performed as follows: to 20 ml of the reverse transcription
reaction mixture was added 2 ml of 0.1 M forward primer,
2 ml of 0.1 M reverse primer, 8 ml of 10 3 amplification
buffer (100 mM Tris-HCl, pH 8.3, 500 mM KCl), 12 ml of
25 mM MgCl2, 55 ml of H2O, 0.5 ml of (a-
32P) dCTP
(Amersham Pharmacia Biotech, Buckinghamshire, En-
gland) and 0.5 ml (2.5 U/100 ml) of Taq polymerase. The
primers for the amplification of the IP3 receptor (type 1)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were designed from published sequences. For the IP3
receptor, they were based on human sequences (10): at
positions 5162 to 5184 (sense primer, 59-GGT TTC ATT
TGC AAG TTA ATA AAG-39) and 5543 to 5566
(antisense primer, 59-AAT GCT TTC ATG GAA CAC
TCG GTC-39) (predicted length of the PCR product, 405
base pair [bp]). For GAPDH they were based on human
sequences (11): at positions 102 to 125 (sense primer,
59-CTT CAT TGA CCT CAA CTA CAT GGT-39) and
805 to 828 (antisense primer, 59-CTC AGT GTA GCC
CAG GAT GCC CTT-39) (predicted length of the PCR
product, 726 bp). Next, 100 ml of reaction mixture was
overlaid with 20 ml mineral oil, and cycling was performed
24 times by means of a thermal cycler (Perkin Elmer/Cetus,
San Diego, California) using the following parameters:
denaturation at 94°C for 1 min, annealing at 60°C for
1 min, extension at 72°C for 2 min, followed by a final
incubation at 72°C for 7 min.
Sequencing of the cardiac IP3 receptor cDNA. Heart
total RNA was reverse transcribed into single strand cDNA
and amplified under the same conditions as above. The
amplified products were separated on a 1% agarose gel, then
isolated from the gel using an Easytrap Ver.2 Kit (Takara,
Tokyo, Japan). Nucleotide sequencing was performed by
Sanger’s method (12) using a DNA Sequencer ABI PRISM
377 XL (PE Applied Biosystem, Foster City, California).
Quantitation of PCR products. The optimal number of
amplification cycles needed to allow quantitation of cardiac
IP3 receptor and GAPDH gene PCR products was deter-
mined. The PCR products for each cycle were subjected to
5% polyacrylamide gel electrophoresis and autoradiography,
and the associated radioactivity was measured using an
imaging analyzer (model BAS-2000; Fuji Photo Film Co.,
Tokyo, Japan). The optimal number of cycles was found to
be 24 for both the cardiac IP3 receptor and GAPDH.
Assessment of expression of cardiac IP3 receptor mRNA.
The relative radioactivity associated with cardiac IP3 recep-
tor PCR products in each sample was calculated by dividing
the radioactivity associated with the IP3 receptor PCR
products by the radioactivity associated with the GAPDH
gene product (internal control; amplified simultaneously).
Each level of RT-PCR product was obtained as the average
of duplicate data. We used GAPDH as an internal control
because the densitometric scores for the mRNAs did not
differ between the groups of patients. Furthermore, this
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enzyme of the glycolytic pathway is constitutively expressed
in most tissues and is the most widely accepted internal
control in the molecular biology literature (13).
Light microscope immunohistochemistry. For immuno-
staining of the IP3 receptor, frozen tissue was allowed to
equilibrate to cryostat temperature (230°C) and was em-
bedded in O.C.T. Compound (Sakura Finetechnical Co.
Ltd., Tokyo, Japan). Then, 4 mm sections were cut,
mounted on slides and dried at room temperature for 6 h.
Immunostaining was performed using the avidin-
biotinylated peroxidase complex. The sections were pre-
treated with 3% H2O2 in absolute methanol to quench
endogenous peroxidase activity. Endogenous avidin and
biotin were blocked according to the manufacturer’s recom-
mendations (Dako LSAB Kit, Dako Co., Carpinteria,
California). After equilibration in phosphate-buffered sa-
line, the sections were blocked with 5% bovine serum
albumin. Anti-IP3 receptor antibody (Affinity Bioreagents,
Inc., Golden, CO) (1:50) was applied to alternate serial
sections, and these were then incubated for 12 h at room
temperature. After washing, the sections were incubated in
biotinylated goat anti-rabbit IgG for 1 h. After three more
washes, the sections were incubated with the avidin-biotin
complex from a standard peroxidase kit (Dako LSAB Kit,
Dako Co., Carpinteria, California).
Statistical analysis. All data are presented as mean 6 SD.
Comparisons between data were made by one-way analysis
of variance followed by Fisher’s exact test. Differences were
taken to be significant at p , 0.05.
RESULTS
Clinical characteristics and hemodynamic data. The pre-
operative hemodynamic, echocardiographic and clinical data
for the three groups are shown in Table 1. None of the
patients with MVD who had NSR nor any of the control
patients had a documented history of AF. Patient number 6
in the MVD 1 AF group had a VVI type pacemaker
(Medtronic Inc., Minneapolis, Minnesota) for one year
before the operation. The values for left ventricular ejection
fraction were within the normal range in all three groups.
Although right atrial pressure (RAP) tended to be higher in
patients with MVD who had AF than they were in patients
with MVD who had NSR or in control patients, there was
no statistically significant difference among the groups.
However, pulmonary capillary wedge pressure (PCWP) and
left atrial diameter (LAD) were both larger in patients with
MVD who had either AF or NSR than they were in control
patients. In patients with MVD who had AF, LAD was
significantly larger than in patients with MVD who had NSR.
Analysis of IP3 receptor expression by the Western blot
method. Figure 1 shows the expression level of the IP3
receptor protein in right atrial tissue from patients with
MVD who had either AF or NSR and from control
patients. The level was significantly higher in patients with
MVD who had AF (0.75 6 0.26) than it was in patients
with MVD who had NSR (0.42 6 0.13), and both values
were significantly higher than that obtained for the control
group (0.14 6 0.08).
Figure 1. Expression level of inositol 1,4,5 trisphosphate receptor (IP3R) protein in the right atrial tissue of patients with either atrial fibrillation (AF) or
normal sinus rhythm (NSR) and representative data showing the levels of the protein. In patients with mitral valvular disease (MVD) who have AF, the
expression level was significantly higher than that found in patients with MVD who had NSR. In both groups of patients with MVD (who had AF or NSR),
the expression level was also significantly greater than it was in the control group. Data are mean 6 SD.
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Next, the data for the expression level of IP3 receptor
protein in the right atrium were pooled for all 26 patients
and broken down according to the patient’s LAD, PCWP
or RAP. As shown in Figure 2: i) the relative expression
level was 0.66 6 0.28 in those patients with a larger LAD
($40 mm) and 0.14 6 0.08 in the those with a smaller
LAD (,40 mm), and there was a significant difference
between these two groups. For PCWP (ii in Fig. 2), the
relative expression level was 0.73 6 0.26 in those with a
higher PCWP ($10 mm Hg) and 0.23 6 0.16 in those
with a lower PCWP (,10 mm Hg), the difference being
significant. The relative expression level of IP3 receptor
protein in patients with a higher RAP ($5 mm Hg)
(0.67 6 0.35) was greater than it was in those with a lower
RAP (,5 mm Hg) (0.32 6 0.21) (iii in Fig. 2).
Analysis of expression levels of the mRNA for the IP3
receptor. We next examined the expression levels of the
mRNAs encoding the IP3 receptor using total RNA ex-
tracted from the patient’s atrial tissues. Figure 3 shows these
levels for patients with MVD who had AF or NSR and for
control patients. The expression level was significantly
higher in homogenates prepared from the right atrium of
patients with MVD who had AF (0.028 6 0.008) than it
was in those from the right atrium of control patients
(0.015 6 0.004). There was no significant difference in this
expression level between patients with MVD who had AF
and patients with MVD who had NSR (0.020 6 0.006).
When data from all 26 patients (patients with MVD who
had AF or NSR and controls) were analyzed together, a
positive correlation (r 5 0.681) was found between the
expression level of IP3 receptor protein and that of its
mRNA (Fig. 4).
Next, the data for the expression levels of IP3 receptor
mRNA in the right atrium were pooled for all 26 patients
and broken down according to the patient’s LAD, PCWP
Figure 2. Relation between the expression level of inositol 1,4,5 trisphosphate receptor (IP3R ) protein in the right atrium of all patients and the magnitude
of left atrial dimension (LAD) (i), pulmonary capillary wedge pressure (PCWP) (ii) and right atrial pressure (RAP) (iii). The expression level was
significantly greater in those patients with a higher LAD, PCWP or RAP. Data are mean 6 SD.
Figure 3. Expression level of inositol 1,4,5 trisphosphate receptor (IP3R)
messenger RNA (mRNA) in the right atrial tissue of patients with either
atrial fibrillation (AF) or normal sinus rhythm (NSR) and representative
data showing the levels of the mRNA. In patients with mitral valvular
disease (MVD) who have AF, the expression level of the mRNA was
significantly higher than it was in the control group. The expression level
in patients with MVD who had AF tended to be higher, though not
significantly, than it was in patients with MVD who have NSR. Data are
mean 6 SD. GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase.
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or RAP. Figure 5 (i) shows that the relative expression level
of IP3 receptor mRNA was 0.025 6 0.007 in those patients
with a larger LAD ($40 mm) and 0.015 6 0.004 in those
with a smaller LAD (,40 mm) and that there was a
significant difference between these two groups. For
PCWP (ii in Fig. 5), the corresponding values were
0.025 6 0.006 in those with a higher PCWP
($10 mm Hg) and 0.018 6 0.007 in those with a lower
PCWP (,10 mm Hg), the difference being significant.
The relative expression level tended to be greater in those
with a higher RAP ($5 mm Hg) (0.024 6 0.008) than it
was in those with a lower RAP (,5 mm Hg) (0.020 6
0.007), but the difference did not reach significance (iii in
Fig. 5).
Immunohistochemistry by light microscopy. Figure 6
shows the immunolocalization of the IP3 receptor at the
light microscopic level in right atrial tissues from represen-
tative patients. Immunoreactivity for the IP3 receptor was
found both within the cytosol and at the nuclear envelope of
cardiac myocytes. In patients with MVD, IP3 receptor
expression was greater than it was in the control both in the
cytosol and at the nuclear envelope.
Figure 4. The relation between the expression levels of inositol 1,4,5 trisphosphate receptor (IP3 receptor) protein and messenger RNA (mRNA). There
was a positive correlation between the expression levels of protein and mRNA. Data are included for all 26 patients studied.
Figure 5. Relation between the expression level of inositol 1,4,5 trisphosphate receptor (IP3 receptor) messenger RNA (mRNA) in the right atrium of all
patients and the magnitude of left atrial dimension (LAD) (i), pulmonary capillary wedge pressure (PCWP) (ii) and right atrial pressure (RAP) (iii). The
expression level was significantly greater in those patients with a higher LAD or PCWP. The expression level tended to be greater, though not significantly,
in patients with a higher RAP. Data are mean 6 SD. Compare these results with those for IP3 receptor protein in Figure 2.
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DISCUSSION
The main findings of this study were twofold. First, in
patients with chronic AF due to MVD, there were signif-
icant increases in the expression levels of IP3 receptor
protein and mRNA in the right atrium, and the expression
of the IP3 receptor was increased (compared with that of
patients in the control group) both in the cytosol and at the
nuclear envelope of atrial myocytes. Second, in all patients:
1) there was a significant positive correlation between the
expression levels of IP3 receptor protein and its mRNA, and
2) the expression levels of IP3 receptor protein and mRNA
in the right atrium were greater at higher levels of left atrial
dimension or PCWP (although these expression levels were
not significantly affected by the level of RAP). To our
knowledge, although some investigators (6,14,15) have
suggested that changes in IP3/Ca21 signaling may be
important in cardiac arrhythmogenesis, this is the first
investigation in which an up-regulation of IP3 receptor
protein and mRNA levels have been detected in the atrium
of patients with chronic AF as compared with patients with
NSR. In contrast, other Ca21 regulatory proteins (RyR) are
down-regulated (2). The alterations we have detected in
RyR (2) and IP3 receptors might result in the establishment
of an abnormal cytoplasmic Ca21 concentration and, as a
consequence, initiate or perpetuate changes in the electro-
physiologic properties of atrial tissue that, in turn, initiate or
perpetuate AF.
Up-regulation of IP3 receptor in patients with MVD
who have chronic AF. In addition to the RyR, a second
type of Ca21 release channel, the IP3 receptor, was identi-
fied on the endoplasmic reticulum of rodent brain and
smooth muscle cells (16,17). A few years later, the IP3
receptor expressed in cardiac myocytes was found to be
structurally very similar to the type 1 IP3 receptor expressed
in vascular smooth muscle and the cerebellum (4). The
dominant mechanism underlying excitation-contraction
coupling in cardiac muscle is Ca21-induced Ca21 release via
the RyR (14,18), and the properties of the IP3 receptor
seem to be quite different from those of the Ca21 gated
Ca21 release channel (RyR). Go et al. (15) showed that
RyR and IP3 receptors were regulated in opposite directions
in failing human hearts, the RyR mRNA levels being
decreased while the IP3 receptor mRNA levels were in-
creased. Recently, we reported a decrease in SR Ca21
release function, as well as a decrease in the number of RyR,
during the development of volume-overloaded heart failure
(19), and we also showed that there were significant
decreases in the number of RyR and the expression level of
RyR mRNA in patients with chronic AF due to MVD (2).
The important finding of our studies is that not only is there
this down-regulation of RyR receptor protein and mRNA
levels in patients with chronic AF due to MVD, but there is
also an increase in the expression of the IP3 receptor. These
results are consistent with the observations of Go et al. (15)
on the failing human myocardium (see preceding text).
Possibly, mechanical overload of the atrial myocardium
might initially cause a down-regulation of RyR, and the
alternative pathway for the regulation of intracellular Ca21
(via the IP3 receptor Ca21 release channel) might then
undergo an up-regulation and, thus, serve as a significant
compensatory mechanism.
Interestingly, in the patients with MVD examined in this
study, an increased immunoreactivity for the IP3 receptor
was found at the nuclear envelope as well as in intracellular
Figure 6. Immunostaining for inositol 1,4,5 trisphosphate receptor (IP3
receptor) protein in the atrial myocardium. In a control patient (A),
immunoreactivity for IP3R protein was found within the cytosol and at the
nuclear envelope of myocytes. In patients with mitral valvular disease with
either normal sinus rhythm (B) or atrial fibrillation (C), the expression was
increased both in the cytosol and at the nuclear envelope.
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membranes. In fact, Humbert et al. (20) previously reported
the existence of the IP3 receptor at the nuclear membrane,
and IP3 has been shown to trigger an increase in nucleo-
plasmic Ca21 (21,22). Ca21 has been shown to be involved
in the regulation of such typical nuclear functions as gene
expression and DNA breakdown, repair and replication
(23). In patients with MVD, mechanical overload of the
myocardium might cause an over-expression of IP3 recep-
tors in the nuclear envelope as a way of controlling the
nucleoplasmic Ca21 concentration (thus regulating cellular
biological functions, metabolism or hypertrophic reactions).
If so, intracellular Ca21 release, via the IP3 receptor, might
be a critical step in the control of cellular metabolism in such
patients.
Up-regulation of the IP3 receptor and its possible rela-
tion to the mechanisms causing chronic AF. In addition
to regulating contractility and facilitating cellular metabo-
lism in the diseased myocardium, the IP3/Ca21 signaling
pathway may play a pathological role in cardiac arrhythmo-
genesis (14). Gorza et al. (24) suggested that Ca21 release
via IP3 receptors may be causally related both to an increase
in automaticity and the generation of some arrhythmias.
They also reported an increased accumulation of IP3 recep-
tor mRNA in atrial myocytes in the senescent heart, and
they speculated that an increased expression of IP3 receptors
in cardiac myocytes might play a pivotal role in the
regulation of chronotropism (24). In cardiac muscle, the
development of a high myoplastic Ca21 level during diastole
(. 500 nM) due to intracellular Ca21 oscillations appears to
induce an abnormal transient inward current (25,26). Fur-
ther, data from skinned cardiac cells suggest that IP3 may
only play a pathological role in cardiac arrhythmogenesis by
enhancing spontaneous Ca21 oscillations (27). In our study,
the expression levels of IP3 receptor protein and its mRNA
were increased in the right atrium of patients with MVD
(perhaps by way of compensation for down-regulation of
the RyR receptor), and, moreover, these expression levels
were higher in patients with MVD who had AF than they
were in patients with MVD who had NSR. Conceivably,
the increased IP3 receptor expression in the atrium of
patients with MVD may be causally related to the tendency
for AF to be initiated or perpetuated in such patients.
It is well known that most tachyarrythmias begin with an
early premature beat. After the wave front spreads from the
premature site, the spatially inhomogeneous properties of
the cellular network alter the excitation wave sufficiently to
create an asymmetry of conduction, and circus movement
reentry ensues (28). Recent electrophysiologic and clinical
evidence suggests an expanded picture that points to an
adaptive structural mechanism—the distribution of gap
junctions associated with the development of microfibrosis
(28)—as the major cause of most forms of AF. Moreover, a
disturbance of side-to-side electrical coupling between cells
(nonuniform anisotropy) is thought to play a central role in
the genesis of AF (29). Sneyd et al. (30) postulated the
following mechanism for intercellular wave propagation.
Mechanical stimulation of a single cell initiates the produc-
tion of IP3 in that cell and a consequent release of Ca21.
Some of this IP3 moves through gap junctions to neigh-
boring cells, releasing Ca21 from their internal stores. A
small amount of IP3 can stimulate a large release of Ca21
via a positive-feedback process (whereby Ca21 stimulates its
own release through the IP3 receptor). The sequential
movement of IP3 through ever more distal cells results in a
corresponding intercellular Ca21 wave. Interestingly, the
IP3 receptor has been reported to be present in ventricular
and atrial myocytes and localized to the region of the gap
junction, and the gap junction serves an important role in
intercellular electrical coupling so that heart muscle is
electrically synchronized (5). In our study we looked for
evidence of an abnormal expression of IP3 receptors in the
gap junction area, but we could find no such evidence.
However, if others or we can find an abnormal dispersion of
IP3 receptors around gap junctions in patients with AF, it
will be suggestive evidence linking IP3 receptor up-
regulation causally with the conduction disturbances that
initiate or perpetuate reentrant arrhythmias.
Study limitations. In our study, we enrolled as control
patients with ischemic heart disease, but with NSR. How-
ever, they were not completely “normal,” and their right
atrium might have been affected. Nevertheless, the hemo-
dynamic data obtained by reviewing the results of preoper-
ative cardiac catheterization and echocardiography were
normal, and these control patients did not exhibit signs of
right atrial overload.
An additional limitation was that we could not perform
detailed histopathological and electrophysiological exami-
nations of right atrial tissues because of the difficulty of
performing studies on human tissues, and the size of the
myocardial tissue sample that could be obtained from the
patients during surgery was critically limited. We have
speculated that the increase of IP3 receptors may cause
changes in cellular excitability, but we did not directly show
the evidence that the increase of IP3 receptors has “func-
tional” consequences on cardiac electrophysiology. Clearly,
an examination of electrophysiology in human atrial myo-
cytes from patients with chronic AF would be of great
interest. Although we could not carry out an electrophysi-
olgical study on small samples, the changes of SR Ca21
regulatory proteins could, at least in part, contribute to the
maintenance of AF.
Conclusions. Several investigators have discussed intracel-
lular Ca21 abnormality as a possible initiator or perpetuator
of AF. However, there has been a lack of direct evidence of
abnormalities in the modulators of intracellular Ca21 ho-
meostasis. In this study, we report that chronic mechanical
overload of the atrial myocardium is associated with an
increase in the expression level of the IP3 receptor and that
this level was greater in patients with chronic AF. These
results suggest that, in patients with chronic AF, up-
regulation of IP3 receptors may be important in modulating
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intracellular Ca21 homeostasis and, possibly, in the initia-
tion or perpetuation of AF.
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